Effect of bladder volume on measured intravesical pressure: a prospective cohort study

INTRODUCTION: Correct bedside measurement of intra-abdominal pressure (IAP) is important. The bladder method is considered as the gold standard for indirect IAP measurement, but the instillation volumes reported in the literature vary substantially. The aim of this study was to evaluate the effect of instillation volume on intra-bladder pressure (IBP) as an estimation for IAP in critically ill patients. METHODS: In this prospective cohort study in 13 sedated and mechanically ventilated patients, we used a revised closed system repeated measurement technique for measurement of IBP. After the system was flushed, IBP was measured with 25 ml increments up to 300 ml. The absolute bias for each volume was calculated as IBP at a given volume minus IBP at zero volume. RESULTS: In total, 30 measurement sets were performed (mean 2.3 per patient). The median IBP at 25 ml was already significantly higher than IBP at zero volume (7.5 versus 6 mmHg). There was no correlation between IBP at zero volume and absolute IBP bias at any bladder volume. Median absolute IBP bias was 1.5 mmHg at 50 ml; 2.5 mmHg at 100 ml; 5.5 mmHg at 150 ml; and up to 11 mmHg at 300 ml. CONCLUSION: Larger instillation volumes than the usually recommended 50 ml to estimate IAP by bladder pressure may cause clinically relevant overestimation of IAP. Small volumes to a maximum of 25 ml, enough to create a fluid column and to remove air, may be sufficient

The pursuit of self-esteem and its motivational implications

Although recent studies have found contingent self-esteem (CSE) to be negatively related to individuals' well-being, research concerning its implications for motivation and engagement is scarce. In two studies, we investigated the relation between CSE, motivation, and engagement in achievement-related situations. A first cross-sectional study among second year high school students (N = 641; 54.1% female) confirmed the hypothesized motivational ambiguity associated with academic CSE. Beyond the contribution of academic self-esteem, academic CSE was positively related to behavioral and emotional engagement, but also to emotional disaffection and test anxiety. These associations could partially be explained by motivational quality, as CSE was also positively related to both autonomous and controlled types of motivation. In a second experimental study among university students (N = 72; 70.8% female), who participated in a tangram puzzle task under varying feedback circumstances, global CSE related to more tension, while predicting less behavioral task perseverance. These effects were not moderated by the type of feedback provided (i.e., positive vs. negative). Theoretical and practical implications of these results are discussed

Education Energy

Team Education Energy formed at Grand Valley State University’s Traverse City campus in the winter of 2015 through a course called “Wicked Problems in Sustainability” (LIB 322). For their project Team Education Energy reached out to Traverse City West Middle School with the idea to create an energy fair. The mission of the project was to help promote ideas of environmental stewardship and to engage and utilize student’s creativity in contributing to the solution of energy efficiency and energy use. The middle school students formed teams and used these concepts to determine what energy efficiency improvements could be made within the school and how they could be made. Team Education Energy met with Heather Wares’ advanced placement science class and discussed energy usage and encouraged the students to come up with solutions for their school that could be implemented. By involving young people and their school community in the project, the Team Education Energy was able to facilitate and encourage creativity, teamwork, dialogue, and problem solving skills while building a more sustainable future. Due to the team’s project, the kids were better able to understand what energy efficiency encompassed, how they could help reduce energy usage and how they might make sustainable energy options more viable in their school. Team Energy Education solicited stakeholders from northwest Michigan for judging the middle school students’ ideas and the winning team members were given a prize ($50.00 fun pass to Crystal Mountain Resort). The community stakeholders were chosen based on their ability to assist in the execution of the winning idea and their knowledge of energy issues/solutions. An additional project objective was to inspire other schools to provide a similar platform for young people offering hands-on experience and support while learning to better their community’s future

PET-CT Suggestive of Lymphoma but Spirochetes in Lymph Node Biopsy: Careful for Prozone Phenomenon in Syphilis

Image in Clinical Medicin

Clinical implications of measurable residual disease in AML : review of current evidence

Despite the fact that 80% of adult acute myeloid leukaemia patients reach complete morphological remission after induction chemotherapy, many of them relapse. Many studies have shown that detection of minimal residual disease (defined as 'any detectable evidence of persistent leukaemic cells during complete morphological remission') has an added value in prediction of relapse and survival, and is more than just a surrogate marker for already known risk factors in AML. As such, the behaviour of the disease during treatment might become equally or even more important to decide whether or not an upgrade of treatment (such as an allogeneic stem cell transplantation) is necessary to improve outcome. However, there are still many open issues as to what the ideal time point is to measure MRD, which threshold is clinically significant, what sample (peripheral blood or bone marrow) should be used and how we can standardize tests so that results from different labs become comparable. This review gives an overview of currently available evidence regarding technical issues, prognostic impact and MRD-directed treatment in AML

Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial

Terapia de inducción estándar; Volasertib adyuvante; Leucemia mieloide agudaStandard Induction Therapy; Adjunctive Volasertib; Acute Myeloid LeukemiaTeràpia d'inducció estàndard; Volasertib adjuvant; Leucèmia mieloide agudaIn this phase 3 trial, older patients with acute myeloid leukemia ineligible for intensive chemotherapy were randomized 2:1 to receive the polo-like kinase inhibitor, volasertib (V; 350 mg intravenous on days 1 and 15 in 4-wk cycles), combined with low-dose cytarabine (LDAC; 20 mg subcutaneous, twice daily, days 1–10; n = 444), or LDAC plus placebo (P; n = 222). Primary endpoint was objective response rate (ORR); key secondary endpoint was overall survival (OS). Primary ORR analysis at recruitment completion included patients randomized ≥5 months beforehand; ORR was 25.2% for V+LDAC and 16.8% for P+LDAC (n = 371; odds ratio 1.66 [95% confidence interval (CI), 0.95–2.89]; P = 0.071). At final analysis (≥574 OS events), median OS was 5.6 months for V+LDAC and 6.5 months for P+LDAC (n = 666; hazard ratio 0.97 [95% CI, 0.8–1.2]; P = 0.757). The most common adverse events (AEs) were infections/infestations (grouped term; V+LDAC, 81.3%; P+LDAC, 63.5%) and febrile neutropenia (V+LDAC, 60.4%; P+LDAC, 29.3%). Fatal AEs occurred in 31.2% with V+LDAC versus 18.0% with P+LDAC, most commonly infections/infestations (V+LDAC, 17.1%; P+LDAC, 6.3%). Lack of OS benefit with V+LDAC versus P+LDAC may reflect increased early mortality with V+LDAC from myelosuppression and infections.This study was funded by Boehringer Ingelheim

Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase-Positive Lymphoma Patients

Anaplastic lymphoma kinase (ALK)-positive lymphomas respond to chemotherapy, but relapses, which bear a poor prognosis, occur. Crizotinib inhibits ALK in vitro and in vivo and was administered as monotherapy to 11 ALK+ lymphoma patients who were resistant/refractory to cytotoxic therapy. The overall response rate was 10 of 11 (90.9%; 95% confidence interval [CI] = 58.7% to 99.8%). Disease status at the latest follow-up is as follows: four patients are in complete response (CR) (months >21, >30, >35, >40) under continuous crizotinib administration; 4 patients had progression of disease (months 1, 2, 2, 2); 1 patient obtained CR on crizotinib, received an allogeneic bone marrow transplant, and is in CR; 2 patients (treated before and/or after allogeneic bone marrow transplant) obtained and are still in CR but they have stopped crizotinib. Overall and progression-free survival rates at 2 years are 72.7% (95% CI = 39.1% to 94.0%) and 63.7% (95% CI = 30.8% to 89.1%), respectively. ALK mutations conferring resistance to crizotinib in vitro could be identified in relapsed patients. Crizotinib exerted a potent antitumor activity with durable responses in advanced, heavily pretreated ALK+ lymphoma patients, with a benign safety profil